Imperial College Innovations Limited Licenses T Cell Receptor (TCR) Therapy Technology To GANYMED Pharmaceuticals AG 
10/19/2005 5:09:21 PM

Transaction valuation potentially £1 million plus royalties on future product sales. Imperial College Innovations Ltd announced today an agreement to license exclusively patents covering the use of T Cell Receptor (TCR) Therapy Technologies and the production of TCRs, developed by Professor Hans Stauss in the Department of Immunology at Imperial College London, to GANYMED Pharmaceuticals AG.